We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Breast Ultrasound Combined with MRI Distinguishes Between Benign and Cancerous Lesions More Accurately

By MedImaging International staff writers
Posted on 10 Nov 2023
Image: Ultrasound combined with MRI is better able to identify cancerous lesions in breast tissue (Photo courtesy of 123RF)
Image: Ultrasound combined with MRI is better able to identify cancerous lesions in breast tissue (Photo courtesy of 123RF)

In breast imaging, nonmass-like lesions, which are areas in the breast with altered echotexture and no definitive shape, pose a diagnostic challenge. A new study has highlighted the potential of combining ultrasound and MRI to improve the differentiation between benign and malignant breast nonmass-like lesions.

The study by researchers at Chinese PLA General Hospital (Beijing, China) revealed that using ultrasound in conjunction with MRI is more effective in differentiating between benign and malignant lesions compared to using either method alone. This combined approach could lead to enhanced diagnostic accuracy. Both ultrasound and MRI have limitations that can result in incorrect identification of lesions, often leading to unnecessary biopsies. The research team explored the effectiveness of MRI in distinguishing between benign and malignant lesions after they were initially identified as nonmass-like by ultrasound. The hypothesis was that using two imaging techniques together might be more effective than one alone.

For the study, the researchers created a training dataset involving 180 patients with 183 nonmass-like lesions, comprising 88 benign and 95 malignant cases. Additionally, a validation dataset included 61 patients with 61 lesions, split between 30 benign and 31 malignant cases. The lesions were examined using MRI, ultrasound, and then a combination of both methods. In both datasets, the combined approach was effective in diagnosing cancer. In the training set, the combined method showed significant statistical improvement over MRI or ultrasound alone in terms of area under the curve (AUC) and specificity values. In the validation set, the combined method was superior to ultrasound alone but not to MRI alone.

The study found that malignant lesions had a significantly higher frequency of calcifications than benign lesions. Lesions with calcifications were found to be 5.6 times more likely to be malignant than those without, aligning with previous research indicating a high association of malignancy with hypo-echoic areas on ultrasound with calcifications. The combined method also identified two false-negative lesions, which were small and lacked typical malignant sonographic features, and correctly reclassified 11 false-positive lesions as benign. Pathology results were confirmed through surgical excision or biopsy.

“The integrated diagnostic strategy of US combined with MRI exhibited good performance for breast NMLs compared with either modality used alone, which can improve the diagnostic specificity while maintaining high sensitivity,” noted the researchers.

Related Links:
Chinese PLA General Hospital

Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
Multi-Use Ultrasound Table
Clinton
Computed Tomography System
Aquilion ONE / INSIGHT Edition
Mammo DR Retrofit Solution
DR Retrofit Mammography

Channels

General/Advanced Imaging

view channel
Image: The study developed a marker based on the analysis of routine CT scans of gastric cancer patients treated at UNICAMP. Higher radiodensity values for adipose tissue are linked to a worse prognosis. In contrast, higher values for muscle are linked to a more favorable outcome (Photo courtesy of FCM-UNICAMP)

CT-Derived Biomarker Predicts Outcomes in Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common malignancy worldwide and often shows heterogeneous outcomes even within the same stage. Prognostic estimates typically rely on tumor-centric... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.